Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download ChromeDownload Microsoft Edge
Press release

Sensyne Health Interim Results

Oxford, UK 31 January 2022: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the Clinical AI company, today announces its unaudited financial results for the six months ended 31 October 2021.

January 31, 2022

Lord (Paul) Drayson PhD, CEO of Sensyne Health, commented: 

“This has been a challenging period that has tested the commitment and resilience of Sensyne, its staff and its stakeholders. By focusing on building our patient database in the UK and USA, and by successfully developing and launching the SENSIGHT platform, we have continued to deliver for our customers and their patients, and strengthened the foundations for the future growth in revenues. 
“Whilst our commercial progress in the year to date has been disappointing, we remain confident about the Company’s long-term prospects, given the size of our database, the strength of our medical and data science expertise, the growth of our business development pipeline, and the significant interest SENSIGHT is now generating from potential customers. 
“We continue to believe that maintaining public trust in the use of patient data for medical research and pharmaceutical product development is crucial, and that it depends upon transparency and fairness. Such use has the potential to save lives and reduce healthcare costs significantly. By sticking to our unique double-bottom line business model, working in partnership with the NHS and health systems in a transparent, ethical and fair way, Sensyne believes it is ideally placed to help realise the full potential of AI and Big Data to revolutionise healthcare and build a profitable and sustainable business in the long-term.” 


Operating highlights 

Patient data strategy 
  • Database of anonymised patient data has grown to approximately 48.3 million patient records through its agreements with UK and US health system partners, compared to 6.8 million records in January 2021.
  • Strategic Research Agreements (“SRAs”) signed with Great Ormond Street Hospital for Children and Cambridge University Hospitals NHS Foundation Trust in September and December 2021 respectively to increase total UK anonymised patient records to 12.9 million.
  • Signed first SRAs in the US with Colorado Center for Personalized Medicine, St Luke’s University Health Network and Sentara Healthcare, providing access to 13.4 million de- identified patient records, including access to genomic data.
  • Signed strategic Teaming Agreement with OMNY Health, to enable Sensyne to contract for access to approximately 22.0 million de-identified patient records across multiple therapeutic areas.
  • Increased access to Phesi Inc clinical trial data set from 13.0 million to approximately 42.0 million de-identified patient records as a result of Sensyne’s equity investment in the US virtual clinical trial data company in January 2021.
‍SENSIGHT real world data analytics platform
  • Launched SENSIGHT platform to support rapid analysis of Sensyne’s real-world patient database at scale.
  • Signed first commercial subscriptions for SENSIGHT including deals with Exscientia and RwHealth in December 2021.
Other
  • Agreement with University of Oxford to conduct a multi-omics drug discovery research project in asthma to analyse genetic data sets to identify novel drug targets for patients with severe forms of asthma that do not respond to current standards of care.

Financials

  • Total revenues of £1.0 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £2.3 million).
  • Research and development expenditure of £10.7 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £7.4 million).
  • Adjusted EBITDA loss of £14.7 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £9.5 million).
  • Cash used in operations of £14.7 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £13.3 million).
  • Operating loss of £21.0 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £13.6 million).
  • Cash and cash equivalents of £8.1 million at 31 October 2021 (31 October 2020: £18.6 million).
  • On 26 January 2022, raised up to £11.35 million comprising a first tranche of £6.35 million (and up to a further £5.0 million by mutual consent) through the issue of loan notes and warrants. Existing cash resources of £2.5 million as on 24 January 2022 strengthened following receipt of the first tranche loan proceeds of £5.95 million on 28 January 2022.

The Company published a Circular on 26 January 2022 to approve, among other resolutions, the issue of warrants associated with the loan note financing. Shareholders’ attention is drawn to the importance of voting at the General Meeting to be held on 11 February 2022 and the deadline for voting by Proxy of the 9 February 2022. The Circular is available from the Company’s website.

Press release

Sensyne Health Interim Results

January 31, 2022
Oxford, UK 31 January 2022: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the Clinical AI company, today announces its unaudited financial results for the six months ended 31 October 2021.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, commented: 

“This has been a challenging period that has tested the commitment and resilience of Sensyne, its staff and its stakeholders. By focusing on building our patient database in the UK and USA, and by successfully developing and launching the SENSIGHT platform, we have continued to deliver for our customers and their patients, and strengthened the foundations for the future growth in revenues. 
“Whilst our commercial progress in the year to date has been disappointing, we remain confident about the Company’s long-term prospects, given the size of our database, the strength of our medical and data science expertise, the growth of our business development pipeline, and the significant interest SENSIGHT is now generating from potential customers. 
“We continue to believe that maintaining public trust in the use of patient data for medical research and pharmaceutical product development is crucial, and that it depends upon transparency and fairness. Such use has the potential to save lives and reduce healthcare costs significantly. By sticking to our unique double-bottom line business model, working in partnership with the NHS and health systems in a transparent, ethical and fair way, Sensyne believes it is ideally placed to help realise the full potential of AI and Big Data to revolutionise healthcare and build a profitable and sustainable business in the long-term.” 


Operating highlights 

Patient data strategy 
  • Database of anonymised patient data has grown to approximately 48.3 million patient records through its agreements with UK and US health system partners, compared to 6.8 million records in January 2021.
  • Strategic Research Agreements (“SRAs”) signed with Great Ormond Street Hospital for Children and Cambridge University Hospitals NHS Foundation Trust in September and December 2021 respectively to increase total UK anonymised patient records to 12.9 million.
  • Signed first SRAs in the US with Colorado Center for Personalized Medicine, St Luke’s University Health Network and Sentara Healthcare, providing access to 13.4 million de- identified patient records, including access to genomic data.
  • Signed strategic Teaming Agreement with OMNY Health, to enable Sensyne to contract for access to approximately 22.0 million de-identified patient records across multiple therapeutic areas.
  • Increased access to Phesi Inc clinical trial data set from 13.0 million to approximately 42.0 million de-identified patient records as a result of Sensyne’s equity investment in the US virtual clinical trial data company in January 2021.
‍SENSIGHT real world data analytics platform
  • Launched SENSIGHT platform to support rapid analysis of Sensyne’s real-world patient database at scale.
  • Signed first commercial subscriptions for SENSIGHT including deals with Exscientia and RwHealth in December 2021.
Other
  • Agreement with University of Oxford to conduct a multi-omics drug discovery research project in asthma to analyse genetic data sets to identify novel drug targets for patients with severe forms of asthma that do not respond to current standards of care.

Financials

  • Total revenues of £1.0 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £2.3 million).
  • Research and development expenditure of £10.7 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £7.4 million).
  • Adjusted EBITDA loss of £14.7 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £9.5 million).
  • Cash used in operations of £14.7 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £13.3 million).
  • Operating loss of £21.0 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £13.6 million).
  • Cash and cash equivalents of £8.1 million at 31 October 2021 (31 October 2020: £18.6 million).
  • On 26 January 2022, raised up to £11.35 million comprising a first tranche of £6.35 million (and up to a further £5.0 million by mutual consent) through the issue of loan notes and warrants. Existing cash resources of £2.5 million as on 24 January 2022 strengthened following receipt of the first tranche loan proceeds of £5.95 million on 28 January 2022.

The Company published a Circular on 26 January 2022 to approve, among other resolutions, the issue of warrants associated with the loan note financing. Shareholders’ attention is drawn to the importance of voting at the General Meeting to be held on 11 February 2022 and the deadline for voting by Proxy of the 9 February 2022. The Circular is available from the Company’s website.

Press release

Sensyne Health Interim Results

Sensyne Health Interim Results

January 31, 2022
Oxford, UK 31 January 2022: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the Clinical AI company, today announces its unaudited financial results for the six months ended 31 October 2021.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, commented: 

“This has been a challenging period that has tested the commitment and resilience of Sensyne, its staff and its stakeholders. By focusing on building our patient database in the UK and USA, and by successfully developing and launching the SENSIGHT platform, we have continued to deliver for our customers and their patients, and strengthened the foundations for the future growth in revenues. 
“Whilst our commercial progress in the year to date has been disappointing, we remain confident about the Company’s long-term prospects, given the size of our database, the strength of our medical and data science expertise, the growth of our business development pipeline, and the significant interest SENSIGHT is now generating from potential customers. 
“We continue to believe that maintaining public trust in the use of patient data for medical research and pharmaceutical product development is crucial, and that it depends upon transparency and fairness. Such use has the potential to save lives and reduce healthcare costs significantly. By sticking to our unique double-bottom line business model, working in partnership with the NHS and health systems in a transparent, ethical and fair way, Sensyne believes it is ideally placed to help realise the full potential of AI and Big Data to revolutionise healthcare and build a profitable and sustainable business in the long-term.” 


Operating highlights 

Patient data strategy 
  • Database of anonymised patient data has grown to approximately 48.3 million patient records through its agreements with UK and US health system partners, compared to 6.8 million records in January 2021.
  • Strategic Research Agreements (“SRAs”) signed with Great Ormond Street Hospital for Children and Cambridge University Hospitals NHS Foundation Trust in September and December 2021 respectively to increase total UK anonymised patient records to 12.9 million.
  • Signed first SRAs in the US with Colorado Center for Personalized Medicine, St Luke’s University Health Network and Sentara Healthcare, providing access to 13.4 million de- identified patient records, including access to genomic data.
  • Signed strategic Teaming Agreement with OMNY Health, to enable Sensyne to contract for access to approximately 22.0 million de-identified patient records across multiple therapeutic areas.
  • Increased access to Phesi Inc clinical trial data set from 13.0 million to approximately 42.0 million de-identified patient records as a result of Sensyne’s equity investment in the US virtual clinical trial data company in January 2021.
‍SENSIGHT real world data analytics platform
  • Launched SENSIGHT platform to support rapid analysis of Sensyne’s real-world patient database at scale.
  • Signed first commercial subscriptions for SENSIGHT including deals with Exscientia and RwHealth in December 2021.
Other
  • Agreement with University of Oxford to conduct a multi-omics drug discovery research project in asthma to analyse genetic data sets to identify novel drug targets for patients with severe forms of asthma that do not respond to current standards of care.

Financials

  • Total revenues of £1.0 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £2.3 million).
  • Research and development expenditure of £10.7 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £7.4 million).
  • Adjusted EBITDA loss of £14.7 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £9.5 million).
  • Cash used in operations of £14.7 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £13.3 million).
  • Operating loss of £21.0 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £13.6 million).
  • Cash and cash equivalents of £8.1 million at 31 October 2021 (31 October 2020: £18.6 million).
  • On 26 January 2022, raised up to £11.35 million comprising a first tranche of £6.35 million (and up to a further £5.0 million by mutual consent) through the issue of loan notes and warrants. Existing cash resources of £2.5 million as on 24 January 2022 strengthened following receipt of the first tranche loan proceeds of £5.95 million on 28 January 2022.

The Company published a Circular on 26 January 2022 to approve, among other resolutions, the issue of warrants associated with the loan note financing. Shareholders’ attention is drawn to the importance of voting at the General Meeting to be held on 11 February 2022 and the deadline for voting by Proxy of the 9 February 2022. The Circular is available from the Company’s website.

Press release

Sensyne Health Interim Results

January 31, 2022
Oxford, UK 31 January 2022: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the Clinical AI company, today announces its unaudited financial results for the six months ended 31 October 2021.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, commented: 

“This has been a challenging period that has tested the commitment and resilience of Sensyne, its staff and its stakeholders. By focusing on building our patient database in the UK and USA, and by successfully developing and launching the SENSIGHT platform, we have continued to deliver for our customers and their patients, and strengthened the foundations for the future growth in revenues. 
“Whilst our commercial progress in the year to date has been disappointing, we remain confident about the Company’s long-term prospects, given the size of our database, the strength of our medical and data science expertise, the growth of our business development pipeline, and the significant interest SENSIGHT is now generating from potential customers. 
“We continue to believe that maintaining public trust in the use of patient data for medical research and pharmaceutical product development is crucial, and that it depends upon transparency and fairness. Such use has the potential to save lives and reduce healthcare costs significantly. By sticking to our unique double-bottom line business model, working in partnership with the NHS and health systems in a transparent, ethical and fair way, Sensyne believes it is ideally placed to help realise the full potential of AI and Big Data to revolutionise healthcare and build a profitable and sustainable business in the long-term.” 


Operating highlights 

Patient data strategy 
  • Database of anonymised patient data has grown to approximately 48.3 million patient records through its agreements with UK and US health system partners, compared to 6.8 million records in January 2021.
  • Strategic Research Agreements (“SRAs”) signed with Great Ormond Street Hospital for Children and Cambridge University Hospitals NHS Foundation Trust in September and December 2021 respectively to increase total UK anonymised patient records to 12.9 million.
  • Signed first SRAs in the US with Colorado Center for Personalized Medicine, St Luke’s University Health Network and Sentara Healthcare, providing access to 13.4 million de- identified patient records, including access to genomic data.
  • Signed strategic Teaming Agreement with OMNY Health, to enable Sensyne to contract for access to approximately 22.0 million de-identified patient records across multiple therapeutic areas.
  • Increased access to Phesi Inc clinical trial data set from 13.0 million to approximately 42.0 million de-identified patient records as a result of Sensyne’s equity investment in the US virtual clinical trial data company in January 2021.
‍SENSIGHT real world data analytics platform
  • Launched SENSIGHT platform to support rapid analysis of Sensyne’s real-world patient database at scale.
  • Signed first commercial subscriptions for SENSIGHT including deals with Exscientia and RwHealth in December 2021.
Other
  • Agreement with University of Oxford to conduct a multi-omics drug discovery research project in asthma to analyse genetic data sets to identify novel drug targets for patients with severe forms of asthma that do not respond to current standards of care.

Financials

  • Total revenues of £1.0 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £2.3 million).
  • Research and development expenditure of £10.7 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £7.4 million).
  • Adjusted EBITDA loss of £14.7 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £9.5 million).
  • Cash used in operations of £14.7 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £13.3 million).
  • Operating loss of £21.0 million for the six months ended 31 October 2021 (six months ended 31 October 2020: £13.6 million).
  • Cash and cash equivalents of £8.1 million at 31 October 2021 (31 October 2020: £18.6 million).
  • On 26 January 2022, raised up to £11.35 million comprising a first tranche of £6.35 million (and up to a further £5.0 million by mutual consent) through the issue of loan notes and warrants. Existing cash resources of £2.5 million as on 24 January 2022 strengthened following receipt of the first tranche loan proceeds of £5.95 million on 28 January 2022.

The Company published a Circular on 26 January 2022 to approve, among other resolutions, the issue of warrants associated with the loan note financing. Shareholders’ attention is drawn to the importance of voting at the General Meeting to be held on 11 February 2022 and the deadline for voting by Proxy of the 9 February 2022. The Circular is available from the Company’s website.